Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Schmidt, R; Ropele, S; Pendl, B; Ofner, P; Enzinger, C; Schmidt, H; Berghold, A; Windisch, M; Kolassa, H; Fazekas, F.
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.
J Neurol Neurosurg Psychiatry. 2008; 79(12): 1312-1317. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar


Autor/innen der Med Uni Graz:
Berghold Andrea
Enzinger Christian
Fazekas Franz
Ofner-Kopeinig Petra
Pendl Barbara
Ropele Stefan
Schmidt Helena
Schmidt Reinhold

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
OBJECTIVE: To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression. METHODS: In this randomised, double-blind, placebo-controlled pilot study, 36 patients with moderate AD received 52 weeks of memantine (20 mg/day) or placebo. Patients were re-evaluated after 26 and 52 weeks to measure the change from baseline in several outcome measures including global and regional glucose metabolism, total brain and hippocampal volumes, as well as chemical shift imaging-derived global and regional N-acetylaspartate and myoinositol concentrations. RESULTS: In the total population, global glucose metabolism decreased by 2.3% (p<0.01), total brain volume by 2.1% (p<0.001) and hippocampal volume by 2.7% (p<0.01) after 52 weeks. Chemical shift imaging (CSI) spectra were severely affected by patient-induced artefacts and highly variable. Patients receiving memantine showed less decline in glucose metabolism in all brain areas than patients on placebo. Their loss of hippocampal volume was substantially smaller (2.4% vs 4.0%). No between-group differences were seen for changes in total brain volume. CONCLUSIONS: The results support the use of multimodal imaging including MRI and positron emission tomography (PET) to monitor the progression of moderate AD. CSI yielded unreliable longitudinal results. The data suggest that memantine has potentially protective effects in AD and they can be used for planning larger confirmatory studies on the cerebral effects of memantine.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Alzheimer Disease - diagnosis
Antiparkinson Agents - pharmacology
Biological Markers - pharmacology
Disease Progression - pharmacology
Double-Blind Method - pharmacology
Female - pharmacology
Fluorodeoxyglucose F18 - pharmacology
Glucose - metabolism
Hippocampus - metabolism
Humans - metabolism
Magnetic Resonance Imaging - metabolism
Male - metabolism
Memantine - pharmacology
Middle Aged - pharmacology
Pilot Projects - pharmacology
Placebos - pharmacology

© Meduni Graz Impressum